Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is exhibiting promising results in preliminary patient studies. Current inquiry https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/